Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.38 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23201120 | 0.98 | CYP19A1 (0.38) | CYP19A1EGLN3FDPSHSP90AA1TSHR | |
| SCHEMBL3053118 | 0.91 | CYP19A1 (0.41) | CYP19A1EGLN3FDPSHSP90AA1ALDH1A1 | |
| SCHEMBL8708386 | 0.82 | CYP19A1 (0.35) | CYP19A1EGLN3FDPSALDH1A1HPGD | |
| SCHEMBL4474312 | 0.82 | CYP19A1 (0.35) | CYP19A1EGLN3FDPSHSP90AA1SMN1; SMN2 | |
| SCHEMBL5657617 | 0.78 | CYP19A1 (0.48) | CYP19A1EGLN3FDPSHSP90AA1ALDH1A1 | |
| SCHEMBL8623023 | 0.77 | GAA (0.34) | CYP19A1EGLN3FDPS | |
| SCHEMBL10517398 | 0.71 | CYP19A1 (0.33) | CYP19A1EGLN3FDPSTSHR | |
| SCHEMBL10338984 | 0.69 | EGLN3 (0.56) | CYP19A1EGLN3TSHRALDH1A1MAPT | |
| SCHEMBL9557335 | 0.69 | — | — | |
| SCHEMBL5062698 | 0.69 | KMT2A (0.41) | CYP19A1EGLN3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363649-A1 | ORGANIC COMPOUNDS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-11-17 | — | — | US | disclosed |
| EP-2164825-B1 | DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI SA (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-20130096305-A1 | DEUTERATED HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096305-A1 | DEUTERATED HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096305-A1 | DEUTERATED HIV ATTACHMENT INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| EP-2300443-B1 | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| EP-2300443-B1 | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | PFIZER LTD (GB) | 2012-12-12 | — | — | EP | disclosed |
| US-8263623-B2 | Triazol derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263623-B2 | Triazol derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263623-B2 | Triazol derivatives useful for the treatment of diseases | PFIZER INC. (US) | 2012-09-11 | — | — | US | disclosed |
| US-8076324-B2 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| EP-2300443-A1 | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | Pfizer Limited (GB) | 2011-03-30 | — | — | EP | disclosed |
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | US | disclosed |
| EP-2164825-A1 | DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Sanofi-Aventis (FR) | 2010-03-24 | — | — | EP | disclosed |
| WO-2010004517-A1 | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010004517-A1 | TRIAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DISEASES | PFIZER LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | PFIZER INC | 2010-01-14 | — | — | US | disclosed |
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | PFIZER INC | 2010-01-14 | — | — | US | disclosed |
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | PFIZER INC | 2010-01-14 | — | — | US | disclosed |
| WO-2008148468-A1 | DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010040-A1 | Triazol Derivatives Useful For The Treatment of Diseases | TSLP, IL5, EPX | CYP19A1 119/4885EGLN3 300/4885FDPS 318/4885 |
| US-20100204206-A1 | Di(hetero)arylcyclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them | ATP2A1, ATP2A2, RYR2 | CYP19A1 1220/4885EGLN3 2614/4885FDPS 1981/4885 |
| US-20220363649-A1 | ORGANIC COMPOUNDS | TRPA1, OPRL1, ALG3 | CYP19A1 512/4885EGLN3 150/4885FDPS 1148/4885 |
| US-20130096305-A1 | DEUTERATED HIV ATTACHMENT INHIBITORS | VCAM1, CD4, ICAM1 | CYP19A1 3419/4885EGLN3 106/4885FDPS 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.